MedTrace Logo

Effects of ISOThrive on Bodyweight, Body Composition, Hunger/Satiety and Cardiac Risk Measures in Overweight Adults

NCT02501356 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2020-03-26

No results posted yet for this study

Summary

To compare the effects of daily intake of the ISOThrive supplement vs. a placebo on the primary outcome measure of body weight and secondary outcome measures (hunger/satiety, health-related measures and self-reported quality of life) in a group of overweight but otherwise healthy adults.

Conditions

Interventions

DIETARY_SUPPLEMENT

ISOThrive Supplement

Consumption of ISOThrive supplements for 3 months

DIETARY_SUPPLEMENT

Placebo Supplement

Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months

Sponsors & Collaborators

  • ISOThrive Inc.

    collaborator INDUSTRY

  • Griffin Hospital

    lead OTHER

Principal Investigators

  • David L. Katz, MD, MPH · Yale-Griffin Prevention Research Center

  • Valentine Y. Njike, MD,MPH · Yale-Griffin Prevention Research Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02501356 on ClinicalTrials.gov